Ltci: Treatment Aid For Feline Leukemia (felv), And Fiv Infections
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Ltci: Treatment Aid For Feline Leukemia (felv), And Fiv Infections as PDF for free.
More details
- Words: 826
- Pages: 4
TREATMENT AID FOR FeLV / FIV INFECTIONS
LTCI HAS ARRIVED
Lymphocyte T-Cell Immunomodulator (LTCI) LTCI Indications LTCI is an approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immuno-deficiency Virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, and thrombocytopenia.
LTCI Immunopharmacology Lymphocyte T-Cell Immune Modulator is a potent regulator of CD-4 lymphocyte production and function and increases IL-2 production in animals.
IL-2 Production
Fig. 1: IL-2 Production
LTCI increases the production of IL-2. IL-2 is known to stimulate cytotoxic T-cell responses against viruses. Absorbance (450 nm)
...LTCI has been shown to increase IL-2 production in the Jurkat cell line (Fig. 1). Jurkat cells are a standard cell line used to study T-cell signaling and leukemia.
48 hr. incubation
1.8
24 hr. incubation 1.2
0.6
0
1
10
1000
100
LTCI Concentration (Log)
Hematopoietic Properties
Additionally, LTCI treatment was shown to significantly increase platelet recovery in a chemotherapy induced thrombocytopenia model in mice (Fig. 2).
LTCI 500
Control
400
Platelet Count
It is now accepted that T-cells participate in the production of red and white blood cells and platelets. LTCI, a T-cell immune modulator, has been shown to increase RBC counts in severely anemic cats and increase lymphocyte counts.
Fig. 2: LTCI Stimulated Platelet Recovery
300 200 100 50 0
5
10
15
Days Following Treatment
20
LTCI Safety Data Clients depend on safe products for their pets. Veterinarians demand safe products for treating ill patients. LTCI has completed formal safety testing. The homology of LTCI among mammalian species, as well as, the absence of any observed adverse events in several animal species, suggests that LTCI has a very low toxicity profile.
LTCI Efficacy Data FeLV and FIV Field Trial
Fig. 3: Treatment Effects of LTCI After Three Injections
LTCI has been evaluated in FeLV and FIV symptomatic cats. In a 23 cat study, three weekly injections of LTCI significantly increased lymphocyte counts and increased the quality of life as determined by clinical scores (Fig. 3).
LTCI Has Been Shown to: • Increase CD-4 lymphocyte function • Increase CD-4 lymphocyte numbers • Increase IL-2 production • Increase red cell counts in severely anemic cats
Long Term Data The long-term benefits of treatment have not been clinically established. However, several animals in the field trial that received monthly or bimonthly injections have remained symptom free for long periods. Two patients in the trial also became negative for virus by PCR analysis of bone marrow aspirate. Lymphocyte T-Cell Immunomodulator has received a conditional license from the United States Department of Agriculture. Additional efficacy and potency studies are in progress. LTCI is manufactured by T-Cyte Therapeutics, Inc and is exclusively distributed by IMULAN BioTherapeutics.
p=0.001
70%
p=0.003
60% % improvement
Study summary available at www.IMULAN.com. Additional efficacy studies are in progress.
80%
50% 40%
30% 20% 10% 0%
Lymphocyte Count
Clinical Score
LTCI Use and Monitoring Clinical Signs: The most important monitoring method is clinical improve ment. Each patient should be monitored for clinical signs associated with their infection(s) and a scoring system may be established to monitor patient progress. IMULAN has a standard evaluation form that can be provided upon request. Complete Blood Counts (CBC): Monitoring of blood cell parameters, especially lympho cyte and red cell counts is recommended to evaluate the subject’s progress. CBCs may be done every 2-4 weeks for patients that have lymphopenia and/or anemia.
IMULAN recommends the following general treatment schedule. Month 1: Weekly injections Month 2: Every other week Month 3+: Every 4-6 weeks or as necessary The veterinarian may have to adjust treatment schedules based on individual patient response.
Company IMULAN is Dedicated to Providing Innovative Solutions to Complex Animal Diseases IMULAN BioTherapeutics, LLC is a privately held bio-science company pioneering the development of precision immunomodulators for veterinary medicine. We are dedicated to delivering innovative immune based treatments for a variety of challenging and life threatening animal diseases.
Our policy is to provide veterinarians access to condi tionally approved products for diseases where no current approved therapy is available. Using our technology platforms, IMULAN is rapidly developing new, first-in class biologics, that target fundamental aspects of disease by modulating the immune response and inflammation.
IMULAN has Global Animal Health Rights to the Following Technology Platforms: Lymphocyte T-Cell Immunomodulator (LTCI) is a poly peptide that regulates lymphocyte and cytokine production. LTCI has been conditionally approved for FeLV and FIV infections. Immune Selective Anti-Inflammatory Derivatives (ImSAIDs) are peptides that modulate the immune response to reduce inflammation without the side effects of steroids and non-steroidal anti-inflammatory drugs. Ongoing work in feline asthma and sepsis.
TCR Peptide Vaccines are small peptides that modulate T-helper cell activity. In a variety of studies, TCR peptides have shown the ability to restore cell mediated immunity, normalize Th1/Th2 balance, and reduced morbidity asso ciated with infections. Ongoing work includes feline immune mediated inflammation, canine atopic dermatitis and pyoderma and canine dilated cardiomyopathy.
toll free (877) 892-9595 visit www.IMULAN.com © 2008 IMULAN BioTherapeutics, LLC
LTCI HAS ARRIVED
Lymphocyte T-Cell Immunomodulator (LTCI) LTCI Indications LTCI is an approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immuno-deficiency Virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, and thrombocytopenia.
LTCI Immunopharmacology Lymphocyte T-Cell Immune Modulator is a potent regulator of CD-4 lymphocyte production and function and increases IL-2 production in animals.
IL-2 Production
Fig. 1: IL-2 Production
LTCI increases the production of IL-2. IL-2 is known to stimulate cytotoxic T-cell responses against viruses. Absorbance (450 nm)
...LTCI has been shown to increase IL-2 production in the Jurkat cell line (Fig. 1). Jurkat cells are a standard cell line used to study T-cell signaling and leukemia.
48 hr. incubation
1.8
24 hr. incubation 1.2
0.6
0
1
10
1000
100
LTCI Concentration (Log)
Hematopoietic Properties
Additionally, LTCI treatment was shown to significantly increase platelet recovery in a chemotherapy induced thrombocytopenia model in mice (Fig. 2).
LTCI 500
Control
400
Platelet Count
It is now accepted that T-cells participate in the production of red and white blood cells and platelets. LTCI, a T-cell immune modulator, has been shown to increase RBC counts in severely anemic cats and increase lymphocyte counts.
Fig. 2: LTCI Stimulated Platelet Recovery
300 200 100 50 0
5
10
15
Days Following Treatment
20
LTCI Safety Data Clients depend on safe products for their pets. Veterinarians demand safe products for treating ill patients. LTCI has completed formal safety testing. The homology of LTCI among mammalian species, as well as, the absence of any observed adverse events in several animal species, suggests that LTCI has a very low toxicity profile.
LTCI Efficacy Data FeLV and FIV Field Trial
Fig. 3: Treatment Effects of LTCI After Three Injections
LTCI has been evaluated in FeLV and FIV symptomatic cats. In a 23 cat study, three weekly injections of LTCI significantly increased lymphocyte counts and increased the quality of life as determined by clinical scores (Fig. 3).
LTCI Has Been Shown to: • Increase CD-4 lymphocyte function • Increase CD-4 lymphocyte numbers • Increase IL-2 production • Increase red cell counts in severely anemic cats
Long Term Data The long-term benefits of treatment have not been clinically established. However, several animals in the field trial that received monthly or bimonthly injections have remained symptom free for long periods. Two patients in the trial also became negative for virus by PCR analysis of bone marrow aspirate. Lymphocyte T-Cell Immunomodulator has received a conditional license from the United States Department of Agriculture. Additional efficacy and potency studies are in progress. LTCI is manufactured by T-Cyte Therapeutics, Inc and is exclusively distributed by IMULAN BioTherapeutics.
p=0.001
70%
p=0.003
60% % improvement
Study summary available at www.IMULAN.com. Additional efficacy studies are in progress.
80%
50% 40%
30% 20% 10% 0%
Lymphocyte Count
Clinical Score
LTCI Use and Monitoring Clinical Signs: The most important monitoring method is clinical improve ment. Each patient should be monitored for clinical signs associated with their infection(s) and a scoring system may be established to monitor patient progress. IMULAN has a standard evaluation form that can be provided upon request. Complete Blood Counts (CBC): Monitoring of blood cell parameters, especially lympho cyte and red cell counts is recommended to evaluate the subject’s progress. CBCs may be done every 2-4 weeks for patients that have lymphopenia and/or anemia.
IMULAN recommends the following general treatment schedule. Month 1: Weekly injections Month 2: Every other week Month 3+: Every 4-6 weeks or as necessary The veterinarian may have to adjust treatment schedules based on individual patient response.
Company IMULAN is Dedicated to Providing Innovative Solutions to Complex Animal Diseases IMULAN BioTherapeutics, LLC is a privately held bio-science company pioneering the development of precision immunomodulators for veterinary medicine. We are dedicated to delivering innovative immune based treatments for a variety of challenging and life threatening animal diseases.
Our policy is to provide veterinarians access to condi tionally approved products for diseases where no current approved therapy is available. Using our technology platforms, IMULAN is rapidly developing new, first-in class biologics, that target fundamental aspects of disease by modulating the immune response and inflammation.
IMULAN has Global Animal Health Rights to the Following Technology Platforms: Lymphocyte T-Cell Immunomodulator (LTCI) is a poly peptide that regulates lymphocyte and cytokine production. LTCI has been conditionally approved for FeLV and FIV infections. Immune Selective Anti-Inflammatory Derivatives (ImSAIDs) are peptides that modulate the immune response to reduce inflammation without the side effects of steroids and non-steroidal anti-inflammatory drugs. Ongoing work in feline asthma and sepsis.
TCR Peptide Vaccines are small peptides that modulate T-helper cell activity. In a variety of studies, TCR peptides have shown the ability to restore cell mediated immunity, normalize Th1/Th2 balance, and reduced morbidity asso ciated with infections. Ongoing work includes feline immune mediated inflammation, canine atopic dermatitis and pyoderma and canine dilated cardiomyopathy.
toll free (877) 892-9595 visit www.IMULAN.com © 2008 IMULAN BioTherapeutics, LLC
Related Documents
Feline-feline Hepatic Lipidosis Treatment
July 2020 18
Fiv
July 2020 18
